| 000 | 01868 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250514185658.0 | ||
| 264 | 0 | _c20040917 | |
| 008 | 200409s 0 0 eng d | ||
| 022 | _a1075-122X | ||
| 024 | 7 |
_a10.1111/j.1075-122X.2004.21305.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSuh, W Warren | |
| 245 | 0 | 0 |
_aA phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of unresectable chest wall recurrences. _h[electronic resource] |
| 260 |
_bThe breast journal _c |
||
| 300 |
_a204-10 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aActuarial Analysis |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
| 650 | 0 | 4 |
_aRadiation-Sensitizing Agents _xadministration & dosage |
| 650 | 0 | 4 | _aRadiotherapy, Adjuvant |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aThoracic Wall _xpathology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aSchott, Anne F | |
| 700 | 1 | _aHayman, James A | |
| 700 | 1 | _aSchipper, Matthew J | |
| 700 | 1 | _aShewach, Donna S | |
| 700 | 1 | _aPierce, Lori J | |
| 773 | 0 |
_tThe breast journal _gvol. 10 _gno. 3 _gp. 204-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1075-122X.2004.21305.x _zAvailable from publisher's website |
| 999 |
_c14835886 _d14835886 |
||